ArticleCytotechnology2025
Salidroside alleviates the progression of idiopathic pulmonary fibrosis by regulating ferroptosis.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the fibrosis-inflammation-oxidative stress axis: multifaceted mechanisms of salidroside in chronic organ fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
- LncRNA HOXA11-AS promotes idiopathic pulmonary fibrosis progression via sponging miR-148a-3p and regulating SMAD2.Hereditas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial pneumonia of unknown etiology, characterized by recurrent acute lung injury. This leads to worsening dyspnea and lung function decline. Patients with idiopathic pulmonary fibrosis (IPF) generally have a poor prognosis, often succumbing within 2-3 years of diagnosis, and the five-year survival rate is below 40%. Analysis of gene differences between raw and normal samples in the database, along with gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, suggests that ferroptosis may play a role in the development of pulmonary fibrosis. To test this hypothesis, transforming growth factor beta 1 (TGF-β1) was used to induce fibrosis in vitro, and levels of pulmonary fibrosis markers such as alpha-smooth muscle actin (α-SMA), fibronectin (FSN), and collagen (COL) were measured by enzyme-linked immunosorbent assay (ELISA). The results confirmed successful establishment of the pulmonary fibrosis model in vitro and indicated increased levels of ferroptosis markers, including glutathione (GSH) and iron accumulation. Salidroside, an extract from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.